R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 20/3/20

Proventa International Weekly News 3 years ago By Josh Neil
Proventa International Weekly News

For those of you who’ve lost track of the days in this WFH nightmare, it’s Friday again! Seeing as any pretence of not talking about coronavirus is entirely gone, welcome to:

The Round-up Coronavirus Special

(Part 1 of 12)

UK’S UPGRADED COVID GUIDANCE STILL NOT ENOUGH – Imperial College London scientists have warned that without stricter government intervention, 250,000 people in the UK could die as a result of the COVID-19 pandemic. A new epidemiological computer simulation, using predictions based on virus spread, has suggested that prevention techniques like hand washing or isolation could reduce deaths by half. The study criticised the UK government’s stance and lack of stringent public health measures. 

MODERNA TESTS FIRST PATIENT WITH POTENTIAL CORONAVIRUS VACCINE – Moderna has tested an initial patient with its mRNA-1273 vaccine. This combats the coronavirus by telling the body to create antibodies against a stabilised form of the Spike protein found in SARS-CoV-2. The National Institutes of Health is conducting the study. A phase 2 study is being prepared based on data generated here. 

COVID-19 TO HAVE ‘BIG IMPACT’ ON A THIRD OF U.S. CLINICAL TRIAL SITES – Up to a third of trial sites expected coronavirus to have a ‘big or extremely big’ impact on their day-to-day ability to recruit or engage patients. Additionally, 39% of 170 trial sites believed patients would be less likely to enrol in new trials.

In other news: 

Clinical Trials
Roche initiates first phase 3 study of Actemra/RoActemra to combat COVID-19
National Institute of Allergy and Infectious Diseases begins phase 1 COVID-19 vaccine trial

Manufacturing
Teva and Mylan set to reintroduce malaria drug hydroxychloroquine to combat COVID-19
COVID-19 to disrupt EU pharma drug launches

That’s all for now. See you next week!

Joshua Neil, Editor
Proventa International

To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Clinical Operations, Supply Chain & Pharmacovigilance Strategy Meeting 2020.

More news

RNA Therapeutics: The World’s First mRNA Malaria Vaccine

Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....

2 years ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

RNA Therapeutics: The World’s First mRNA Malaria Vaccine

Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....

2 years ago

Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato

The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...

2 years ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato

The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...

2 years ago

Intrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets

Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...

2 years ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Intrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets

Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...

2 years ago